Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRI-guided focused ultrasound and Definity in skin cancer
NCT05620290Phase 1Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jun 2022
- Primary completion
- Jul 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of perflutren lipid microspheres in Malignant Melanoma (MM) and non-melanoma skin cancer (NMSC), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Adverse Events at 90 days. Started Jun 2022; status: recruiting.
02
Drugs
perflutren lipid microspheres
03
Conditions
Malignant Melanoma (MM)non-melanoma skin cancer (NMSC)
Beyond the preview
Go deeper on NCT05620290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620290.